Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors

Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.

TC Trade Conquest Newsroom November 7, 2026 ·1 min read

Key takeaways

Ginkgo's shift to physical data for AI labs is the thread tying its cost discipline to its hardware ambitions.
On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Ginkgo Bioworks (DNA) announced a strategic transition toward commercializing autonomous laboratory hardware and cloud data services.
For long-term investors, this operational evolution determines whether automated biology can build high-margin revenue streams while reducing cash burn.

Novo Nordisk selected Ginkgo to build an autonomous research laboratory. Ginkgo ended the third quarter with $285 million in cash.

See the latest quote, chart and news for DNA.

Want trade ideas like this in real time? Subscribe to Trade Conquest.